CN116999427A - Application of salvianolic acid B in preparing medicament for treating alopecia - Google Patents
Application of salvianolic acid B in preparing medicament for treating alopecia Download PDFInfo
- Publication number
- CN116999427A CN116999427A CN202311111086.0A CN202311111086A CN116999427A CN 116999427 A CN116999427 A CN 116999427A CN 202311111086 A CN202311111086 A CN 202311111086A CN 116999427 A CN116999427 A CN 116999427A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- hair
- alopecia
- sab
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 title claims abstract description 26
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 title claims abstract description 25
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 21
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims description 10
- 230000003779 hair growth Effects 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims description 17
- 210000003780 hair follicle Anatomy 0.000 claims description 17
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 8
- 230000001276 controlling effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 19
- 210000004209 hair Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- 230000035617 depilation Effects 0.000 description 3
- 230000002951 depilatory effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 210000004919 hair shaft Anatomy 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102100033875 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Human genes 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000640851 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000004185 countercurrent chromatography Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The in-vitro and in-vivo experiments prove that the salvianolic acid B can play a role in controlling alopecia by regulating and controlling a plurality of signal paths, including the important Wnt paths in hair growth, and has great clinical value and economic benefit.
Description
Technical Field
The invention relates to the field of medicines, in particular to application of salvianolic acid B in preparation of a medicine for treating alopecia.
Background
Alopecia (Alopecia) is a generic term for abnormal loss of hair, a common skin condition. In recent years, the number of people suffering from alopecia is gradually increased, the trend of younger people is shown, and many people suffering from alopecia are deeply plagued by the young and middle-aged people. The most common of the alopecia diseases is androgenic alopecia, and epidemiological studies show that the prevalence of the disease in China is 21.3% for men and 6.0% for women, namely, 1 male in 5 China may have androgenic alopecia.
Hair activity and hair shaft growth are regulated by a variety of cells, wherein hair papilla is a specialized mass of fibroblasts located at the bottom of hair follicle, which is capable of inducing hair growth. The hair papilla cells can secrete various cell growth factors, and can regulate proliferation of hair papilla and perifollicular vascular endothelial cells, so that hair papilla angiogenesis is induced; meanwhile, the state of the anagen hair follicle, the duration of the anagen phase, etc. are also affected by the activity of the hair papilla cells. Hair follicles are found in androgenic alopecia and alopecia areata patients to advance to stationary phase, and this process is attended by ROS, which can be prevented or alleviated by antioxidants or ROS inhibitors of hair papilla cells.
At present, the oral medicines approved by the national drug administration for treating alopecia are only two kinds of minoxidil and finasteride. Although widely used clinically, these two drugs cannot completely block the progress of the disease, and have adverse reactions of different degrees. Minoxidil is a vasodilator and potassium channel opener, and its side effects are scalp irritation, itching, dryness, scaling, redness, contact dermatitis, hirsutism, etc. Finasteride is a type II 5 alpha-reductase inhibitor and can block T from being converted into DHT with stronger activity, so that the inhibition of androgens on hair follicles is weakened. But finasteride can cause adverse effects such as impotence, sexual dysfunction, myalgia, female-type breasts, etc. Besides drugs, treatments for alopecia include laser light and hair transplantation, and the effects of these treatments have not been progressed in breakthrough.
Therefore, there is a need in the art for a medicament for treating alopecia with remarkable therapeutic effects and little side effects.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention provides the following technical scheme:
the invention provides application of salvianolic acid B in preparing a medicament for treating alopecia;
further, the salvianolic acid B is shown as a formula I:
further, the hair loss treatment effect is to improve hair follicle activity and promote hair growth.
Salvianolic acid B (Salvianolic acid B, SAB, CAS No. 115939-25-8), salvianolic acid B of formula C 36 H 30 O 16 Relative molecular mass: 718.62. the salvianolic acid B is light yellow, is in powder form, has special smell, and has slightly bitter and astringent taste. The compound can be dissolved in water, ethanol and methanol, and the small molecular compound has a plurality of phenolic hydroxyl groups in the structure and has stronger oxidation resistance.
In the prior art, the sources of salvianolic acid B mainly include two types: firstly, the salvia miltiorrhiza extraction method and secondly, the chemical synthesis method. At present, a plurality of separation and extraction methods are specially used for extracting salvianolic acid B, wherein the salvianolic acid B is prepared by condensing three molecules of salvianic acid A and one molecule of caffeic acid and is obtained by extracting roots and rhizomes of Salvia Miltiorrhiza bge of Labiatae. The main technological process of the separation and preparation of the salvianolic acid B is extraction, separation, purification and other processes. The method for extracting the salvianolic acid B comprises the following steps: traditional water decoction method, ultrasonic extraction method, reflux extraction method, supercritical CO 2 Extraction, etc., and the separation method used is silica gel column chromatography, large Kong Shujiao chromatography, high performance countercurrent chromatography, etc. For the chemical synthesis method, 3-hydroxy-4-methoxybenzaldehyde (isovanillin) is used as a raw material, 4-hydroxy-5-methoxybenzopyran-2-ketone is synthesized through Claisen rearrangement, acetylation and oxidation reaction, aldol condensation reaction is carried out on the 4-hydroxy-5-methoxybenzopyran-2-ketone and methoxyisovanillin, a lactone ring is opened to generate hydroxymethyl, the hydroxymethyl is oxidized to generate aldehyde, trans-2, 3-dihydrobenzofuran is generated through cyclization under the action of hydrobromic acid, and acrylic acid is generated through condensation of aldehyde group and malonic acid, so that salvianolic acid B is obtained. Salvianolic acid B is currently marketed by various companies, such as Sigma, and the preparation method thereof is also known in the prior art.
Drawings
FIG. 1A schematic photograph of hair growth in different groups of unhairing mice
FIG. 2 in vitro culture of hair follicle shaft growth length
FIG. 3 in vitro cultured hair papilla cell ROS levels in different treatment groups
Advantageous effects
Salvianolic acid B (Salvianolic acid B, SAB) is an important water-soluble component of Saviae Miltiorrhizae radix, also called salvianolic acid B, is the only monomer component extracted from Saviae Miltiorrhizae radix on the market at present, and plays an important role in the efficacy of Saviae Miltiorrhizae radix. SAB has effects of resisting platelet aggregation, resisting thrombosis, improving microcirculation, and resisting oxidation injury. The in-vitro and in-vivo experiments prove that the salvianolic acid B can play a role in controlling alopecia by regulating and controlling a plurality of signal paths, including the important Wnt paths in hair growth, and has great clinical value and economic benefit.
Detailed Description
Examples
Test object: c57BL/6 male mice at 8 weeks of age were purchased from the experimental animal center at the university of double denier.
The test method comprises the following steps:
1) In vivo experiments
Establishment of a depilatory mouse model: the method adopts 8-week-old C57BL/6 male mice, adopts the back shaving and combines the dehairing paste mode to establish a dehairing model, and comprises the following specific modes: the razor cleans the back Mao Ti, further treating it with conventional depilatory cream for 1min, and then scrubbing the cream.
Experimental mice were grouped and treated:
(1) Grouping: first, animals were divided into two groups, control group (Control), salvianolic acid B treatment group (SAB). Each group had 6 mice.
(2) Treatment of mice: the control mice were subjected to depilation treatment, and 100ul of physiological saline was subcutaneously injected into the depilation area of the back of each day after depilation; after depilating, 100ul of SAB configured with physiological saline was injected subcutaneously into the back of each day in SAB-treated mice, and the final SAB dose was: 10 mg/kg/day.
(3) The back hair growth status of the mice was observed and photographed.
2) In vitro experiments: detection of hair follicle and papilla cell Activity
(1) In vitro hair follicle tissue culture: hair follicles were placed in 12-well cell culture plates, 1 hair follicle was placed in each well, 1ml of serum-free William's medium was added, and the culture was performed in a cell incubator.
(2) Hair follicle grouping and processing: the in vitro hair follicles were divided into two groups, control group (Control), salvianolic acid B treatment group (SAB). Each group had 6 hair follicles. SAB group SAB mother liquor prepared with PBS was added to give a final concentration of 50. Mu.g/ml. Fresh medium was changed every two days and cultivation was continued for 6 days. Meanwhile, the hairs are photographed, the lengths of the hair shafts are measured, and the difference of the growth rates of different groups of hairs and the difference of the growth periods of hair follicles are evaluated.
(3) Detection of proliferation activity of hair papilla cells: hair papilla cells were grown in DMEM medium containing 10% fetal bovine serum at 37 ℃ with 5% CO 2 Culturing in an incubator. Control cells were cultured only with DMEM and SAB-treated cells were supplemented with SAB to a final concentration of 50. Mu.g/ml. The cell proliferation detection is carried out by using a cell real-time analysis detection system xCELLigence of Roche company. And (3) staining different groups of cells by using DCFH fluorescent dye, and judging the ROS level of the cells by fluorescence intensity.
Test results:
we have found, using the depilatory mouse model, that SAB significantly promotes hair growth, more rapidly promotes hair entry into anagen phase (figure 1), demonstrating the efficacy of SAB in promoting hair growth and its activity. In vitro hair follicle cultures found that SAB promoted human hair shaft growth, with significant differences between model and SAB groups (fig. 2). In addition, the invention performs in vitro cell research on key cells in hair follicle, namely hair papilla cells, and adopts DCFH fluorescent staining, which shows that SAB can significantly promote proliferation of hair papilla cells and can reduce the level of active oxygen in hair papilla cells (figure 3).
Claims (3)
1. Application of salvianolic acid B in preparing medicine for treating alopecia is provided.
2. The use according to claim 1, wherein the salvianolic acid B is represented by formula i:
3. the use according to claim 1 or 2, wherein the alopecia treating effect is an effect of increasing hair follicle activity and promoting hair growth.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311111086.0A CN116999427A (en) | 2023-08-30 | 2023-08-30 | Application of salvianolic acid B in preparing medicament for treating alopecia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311111086.0A CN116999427A (en) | 2023-08-30 | 2023-08-30 | Application of salvianolic acid B in preparing medicament for treating alopecia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116999427A true CN116999427A (en) | 2023-11-07 |
Family
ID=88565561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311111086.0A Pending CN116999427A (en) | 2023-08-30 | 2023-08-30 | Application of salvianolic acid B in preparing medicament for treating alopecia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116999427A (en) |
-
2023
- 2023-08-30 CN CN202311111086.0A patent/CN116999427A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101894229B1 (en) | Functional composition comprising deer antlers derived stem cell culture medium | |
| KR101132246B1 (en) | The hair growth solution mainly comprised of ginsenoside rg3 and rh2, and the hair treatment composition | |
| KR20180048431A (en) | Functional composition comprising deer antlers derived stem cell culture medium | |
| KR101047644B1 (en) | External skin composition containing pogongyoung, horse riding, powder or extract extract | |
| CN101125155B (en) | Application of erigeron breviscapus methanol extracts in skin-whitening and speckle eliminating prevention | |
| KR101835039B1 (en) | Cosmetic composition for improving melasma comprising herbal extract | |
| JP2013112684A (en) | Composition for prevention of depilation or promotion of hair growth | |
| CN115212243A (en) | Application of epimedium extract | |
| JP2014506586A (en) | Novel use of the composition for preventing alopecia (CRIA) caused by chemotherapy and radiation therapy, reducing the impact of CRIA, and improving the appearance of hair regrowth after CRIA | |
| CN116999427A (en) | Application of salvianolic acid B in preparing medicament for treating alopecia | |
| KR20140092093A (en) | Composition for preventing hair loss or promoting hair growth comprising an extract of shell Arachis hypogaea Linne | |
| KR20130040664A (en) | A cosmetic composition comprising an extract of rhus verniciflua stokes for trichogenousness | |
| KR101167510B1 (en) | Composition for preventing hair loss or promoting hair growth comprising an saponin biotransformant of Ginseng | |
| US20230144955A1 (en) | Peptide for preventing or treating hair loss, and use thereof | |
| TWI789553B (en) | Use of hemerocallis fulva linn. extract for manufacturing of a composition for promoting skeletal muscle basal metaboilc rate | |
| KR101724870B1 (en) | Wnt/-catenin Activity promoting composition of Wnt/-catenin signaling with Anthriscus sylvestris Hoffm extract | |
| CN109453294B (en) | Application of Xinmaian in promoting hair growth | |
| JP7161302B2 (en) | Wnt10b production promoter and scalp and hair cosmetic containing the same | |
| KR101313724B1 (en) | The hair growth solution mainly comprised of Ecklonia cava extract, and the hair treatment composition | |
| CN115554380B (en) | Composition for preventing and treating alopecia by acting on hair follicle tissue and application thereof | |
| EP3888625A1 (en) | Composition for scalp and hair | |
| KR101910595B1 (en) | Composition for Treating Hair Loss and Promoting Hair Growth Comprising Terthiophene Derivative | |
| EP1620116B1 (en) | Use of quinquina for the preparation of a medicament stimulating angiogenesis | |
| CN115779028B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN114948932B (en) | Use of a composition comprising mulberenone for the preparation of a product for the prevention and treatment of hair loss by acting on the hair follicle tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |